

This is a repository copy of *HpARI protein secreted by a helminth parasite suppresses interleukin-33*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/122893/>

Version: Accepted Version

Article:

Osbourne, Megan, Soares, Dinesh C., Vacca, Francesco et al. (21 more authors) (2017) HpARI protein secreted by a helminth parasite suppresses interleukin-33. *Immunity*. 739-751.e5. ISSN 1074-7613

<https://doi.org/10.1016/j.immuni.2017.09.015>

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

1 **HpARI protein secreted by a helminth parasite suppresses interleukin-33**

2

3 Megan Osbourn^{1,9}, Dinesh C. Soares^{1,9}, Francesco Vacca^{1,9}, E. Suzanne Cohen², Ian
4 C. Scott², William F. Gregory¹, Danielle J. Smyth^{3,4}, Matilda Toivakka^{1,3}, Andrea M.
5 Kemter^{3,4}, Thierry le Bihan⁵, Martin Wear⁶, Dennis Hoving⁴, Kara J. Filbey³, James
6 P. Hewitson^{3,7}, Holly Henderson¹, Andrea González-Càscar^{1,3}, Claire Errington¹,
7 Sonja Vermeren¹, Anne L. Astier¹, William A. Wallace⁸, Jürgen Schwarze¹,
8 Alasdair C. Ivens³, Rick M. Maizels^{*3,4,10} and Henry J. McSorley^{*1,3,10}

9

10 Current Addresses

11 1. MRC Centre for Inflammation Research, University of Edinburgh, Queen's
12 Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, UK.

13 2. Department of Respiratory, Inflammation and Autoimmunity, MedImmune
14 Ltd, Granta Park, Cambridge, CB21 6GH, UK.

15 3. Institute of Immunology and Infection Research, and Centre for Immunity,
16 Infection and Evolution, School of Biological Sciences, Ashworth Laboratories,
17 University of Edinburgh, West Mains Road, Edinburgh EH9 3JT, UK.

18 4. Wellcome Centre for Molecular Parasitology, Institute for Infection, Immunity
19 and Inflammation, University of Glasgow, Sir Graeme Davies Building
20 120 University Place, Glasgow G12 8TA, UK

21 5. SynthSys, The Kings Buildings, University of Edinburgh, Edinburgh EH9 3BF,
22 UK

23 6. The Edinburgh Protein Production Facility (EPPF), Wellcome Trust Centre for
24 Cell Biology (WTCCB), University of Edinburgh, King's Buildings, Max Born
25 Crescent, Mayfield Road, Edinburgh, EH9 3BF, UK.

26 7. Centre for Immunology and Infection, Department of Biology, University of
27 York, York, UK, YO10 5DD.

28 8. Department of Pathology, Laboratory Medicine, Royal Infirmary of Edinburgh,
29 Edinburgh, UK.

30 9. These authors contributed equally

31 10. Senior author

32 * Corresponding authors henry.mcsorley@ed.ac.uk and
33 Rick.Maizels@Glasgow.ac.uk.

34 Lead contact: Dr McSorley

35

Summary

Infection by helminth parasites is associated with amelioration of allergic reactivity, but mechanistic insights into this association are lacking. Products secreted by the mouse parasite *Heligmosomoides polygyrus* suppress type 2 (allergic) immune responses through interference in the interleukin-33 (IL-33) pathway. Here, we identified *H. polygyrus* Alarmin Release Inhibitor (HpARI), an IL-33-suppressive 26-kDa protein, containing 3 predicted complement control protein (CCP) modules. *In vivo*, recombinant HpARI abrogated IL-33, group 2 innate lymphoid cell (ILC2) and eosinophilic responses to *Alternaria* allergen administration, and diminished eosinophilic responses to *Nippostrongylus brasiliensis*, increasing parasite burden. HpARI bound directly to both mouse and human IL-33 (in the cytokine's activated state), and also to nuclear DNA via its N-terminal CCP module pair (CCP1/2), tethering active IL-33 within necrotic cells, preventing its release, and forestalling initiation of type 2 allergic responses. Thus, HpARI employs a novel molecular strategy to suppress type 2 immunity in both infection and allergy.

Keywords: IL-33, helminth, parasite, allergy, asthma, immunomodulation

55 **Introduction**

56 Infection with helminth parasites negatively correlates with prevalence of
57 allergic disease, and parasitic infection is associated with immunosuppression
58 (Maizels and McSorley, 2016). Many researchers, ourselves included, have
59 demonstrated that helminths release immunomodulatory proteins to control
60 anti-parasite immune responses and maintain their persistence in the host
61 (Maizels and McSorley, 2016). We previously showed that the excretory-
62 secretory products of the mouse intestinal parasite *Heligmosomoides polygyrus*
63 (HES) suppress allergic responses in mouse models of asthma (Buck et al., 2014;
64 McSorley et al., 2015; McSorley et al., 2014; McSorley et al., 2012). HES
65 administration blocks the interleukin-33 (IL-33) response to inhaled *Alternaria*
66 (fungal) allergen (McSorley et al., 2014) leading to reduced type 2 innate
67 lymphoid cell (ILC2) responses and abrogating lung pathology.

68 *IL33* and its receptor (*IL1RL1*) are both among the 10 genes most strongly linked
69 to allergic sensitization (Bonnelykke et al., 2013) and asthma (Bonnelykke et al.,
70 2014; Moffatt et al., 2010) in genome-wide association studies. IL-33
71 concentration is increased in the lungs of severe asthmatics (Castanhinha et al.,
72 2015; Saglani et al., 2013), correlating negatively with lung function
73 (Christianson et al., 2015). Respiratory viral infections are implicated in both
74 initiation and exacerbation of asthma, an effect which is also associated with IL-
75 33 release (Jackson et al., 2014; Saravia et al., 2015).

76 The IL-33 receptor (ST2, IL1RL1, IL-33R) is expressed by a wide range of cells,
77 notably T cells, macrophages, endothelial cells, epithelial cells and ILC2 (Cayrol
78 and Girard, 2014). Through these interactions, IL-33 drives type 2 immune

79 responses in a range of diseases including asthma, atopic dermatitis, food allergy,
80 COPD, eosinophilic inflammatory bowel disease, eosinophilic esophagitis and
81 age-related macular degeneration (De Salvo et al., 2016; Liew et al., 2016; Simon
82 et al., 2015; Tordesillas et al., 2014). IL-33 is a member of the IL-1 family of
83 cytokines. It is stored preformed in the nucleus bound to heterochromatin, and
84 its dominant function is as an alarmin cytokine. Active IL-33 is released from the
85 nucleus under conditions of necrosis, while during apoptosis active caspases
86 cleave IL-33 within its receptor-binding domain, abolishing activity (Lefrancais
87 and Cayrol, 2012). Although the full-length, 30 kDa form of IL-33 is functional,
88 the activity of IL-33 is increased 10-fold through cleavage between the DNA-
89 binding and receptor-binding domains by proteases such as calpain-2 (Hristova
90 et al., 2015), neutrophil elastase, cathepsin G (Lefrancais et al., 2012) and mast
91 cell tryptase (Lefrancais et al., 2014) releasing 18-21 kDa mature forms. Active
92 IL-33 is released in a reduced form, which under physiological conditions rapidly
93 oxidizes, forming new disulfide bonds and changing conformation, rendering it
94 unable to bind to the IL-33R beyond a short temporal and spatial range (Cohen
95 et al., 2015).

96 Here, we identified *H. polygyrus* Alarmin Release Inhibitor (HpARI), a HES-
97 derived recombinant protein that can replicate the IL-33-suppressive effects of
98 total HES. HpARI bound directly to active murine and human IL-33 and nuclear
99 DNA. This dual binding blocked the interaction of IL-33 with its receptor, and
100 tethered IL-33 within necrotic cells, preventing its release, and blocking allergic
101 response initiation. Thus, HpARI prevents initiation of parasite-toxic IL-33-

102 mediated type 2 immune responses and suppresses the development of allergic
103 airway inflammation.

Results

In vitro suppression of IL-33 by HES

Previous studies established that HES ablates detectable IL-33 in the bronchoalveolar milieu after *Alternaria* allergen administration, suppressing downstream allergic responses (McSorley et al., 2014). To further investigate the IL-33-suppressive activity of HES, we developed an *in vitro* assay for IL-33 release: a single cell suspension of naïve total murine lung cells cultured for 1 h in the presence of *Alternaria* allergen and HES. In this assay, HES markedly reduced the amount of IL-33 in culture supernatants, as detected by ELISA (**Figure 1A**).

IL-33 is released from lung epithelial cells under conditions of necrosis, whereas activated caspases cleave IL-33 within the IL-1-like cytokine domain, inactivating IL-33 under conditions of apoptosis (Lefrancais and Cayrol, 2012). We therefore hypothesized that HES could be activating caspase and/or apoptosis pathways. Propidium iodide and annexin V staining showed that cells incubated with *Alternaria* allergen were highly necrotic and that this was unaffected by the presence of HES (**Figure 1B**). Necrosis induced by freeze-thaw treatment of lung cells also resulted in substantial IL-33 release, which again was abrogated by treatment of cells with HES immediately prior to freezing (**Figure 1C**). Therefore we conclude that HES suppression of IL-33 does not depend on activation of the apoptosis pathway, but instead acts on pre-formed IL-33 released from necrotic cells.

Identification and characterization of HpARI protein

A process of fractionation, screening and proteomic analysis of HES was used to identify candidate IL-33-suppressive proteins. Gel filtration and anion exchange FPLC were used to fractionate HES by size and charge, respectively. IL-33 suppressive activity peaked around size fraction 11 (**Figure 2A**) and charge fraction 25 (**Figure 2B**). Each size and charge fraction was subjected to trypsin digestion followed by liquid chromatography-electrospray tandem mass spectrometry (LC-MS/MS), and the exponentially modified protein abundance index (emPAI) value for each HES protein in every fraction was calculated, and compared to the profile of IL-33 suppression.

By size fractionation, 220 proteins were found with emPAI values which peaked around size fraction 11 (peak value in fractions 10-12), while 371 proteins were found with emPAIs which peaked around charge fraction 25 (peak value in fractions 23-27), 54 of which were shared between the two fractionation techniques. Proteins were prioritized wherein more than one peptide was detected in size fraction 11 and charge fraction 25, resulting in a short-list of 25 candidate proteins (**Supplementary Table 1**). The emPAI values for each of these 25 candidates for all size and charge fractions was then manually compared to the IL-33 suppression profile (**Supplementary Figure 1A**), and 4 candidates were selected for initial screening (**Supplementary Figure 1B**).

The 4 candidate IL-33 suppressive genes were transfected into HEK293T cells for expression, and screened for suppression of the IL-33 signal *in vitro*. Of the 4 candidates only Hp_I08176_IG02172_L1157 (candidate “D” in **Figure 2C**) significantly suppressed IL-33; this protein was consequently renamed as *H. polygyrus* Alarmin Release Inhibitor (HpARI).

The *HpARI* gene is made up of 7 exons, encoding a 251-aa protein including a 16-aa signal peptide motif (**Supplementary Figure 2A**), with a deduced mature molecular weight of 26 kDa. The mature protein contains three predicted Complement Control Protein (CCP)-like modules (also known as Short Consensus Repeats (SCRs) or sushi-domains, PFAM00084) (**Figure 2D**). CCP1-3 all contain features of a CCP module such as the four consensus Cysteine residues (Cys^I to Cys^{IV}, consistent with formation of disulfide bonds in a Cys^I-Cys^{III} and Cys^{II}-Cys^{IV} pattern), the Trp/Leu residue between Cys^{III} and Cys^{IV} and other structurally important residues typical of a CCP module (**Figure 2D-E and Supplementary materials and methods**)(Kirkitaдзе and Barlow, 2001; Soares et al., 2005). Compared to archetypal CCP modules (Soares and Barlow, 2005), all three are atypical in part with divergent sequence features, including an absence of conserved Proline residues after Cys^I in CCP1, and atypical insertions of ~20 amino acid residues between Cys^I and Cys^{II} in CCP 2 and CCP3, which are unique compared to previously identified CCP domains. Each CCP module is encoded by two exons with the second exon boundary in each case falling between adjacent predicted CCP modules (i.e. between Cys^{IV} of one module and Cys^I of the next) lending further support to the discerned domain boundaries (**Figure 2E and Supplementary Figure 2A**).

The three predicted *HpARI* CCP module sequences were modelled individually based upon their top ranked CCP module template structures. Each CCP module 3-D model is characterised by a β -sheet framework, held together by two disulfide bridges. Other key structural features such as the location of the buried Trp/Leu, hypervariable loop, and potential N-glycosylation sites are indicated

175 along with the relative positions of the novel insertions in CCP2 and CCP3, which
176 could not be modelled on conventional experimentally determined CCP module
177 structures (**Figure 2F**).

178 *In vitro and in vivo IL-33 suppression by HpARI*

179 Recombinant mature 6-His and Myc-tagged HpARI protein was purified by metal
180 chelating chromatography (**Supplementary Figure 2B**), and tested for IL-33
181 suppression *in vitro*. HpARI was active at <10 ng/ml, while HES required an
182 approximately 50-fold higher concentration for a similar effect (**Figure 3A**). The
183 IL-33-suppressive activity of HpARI in response to *Alternaria* culture or freeze-
184 thaw was ablated on heat-treatment, as with HES (**Supplementary Figure 3A**,
185 **B**).

186 HpARI also effectively suppressed IL-33 detected in bronchoalveolar lavage
187 (BAL) fluids in response to *Alternaria* allergen *in vivo* (**Figure 3B**). Again this
188 effect replicated that of HES (McSorley et al., 2014) and suppression was ablated
189 when HpARI was proteolytically cleaved and heat-treated, ruling out a role for
190 non-protein contaminants. In addition, the IL-33-suppressive effects of HpARI
191 could pre-condition airway tissues, substantially reducing the IL-33 response to
192 *Alternaria* allergen 24 h later, with a degree of protection in some animals even
193 after 72 h (**Figure 3C**). Thus, HpARI appears to be a critical IL-33-suppressive
194 factor in HES.

195 *Suppression of in vivo type 2 responses by HpARI*

196 *Alternaria* exposure induces a rapid T cell-independent eosinophilia within 24 h
197 of administration. This response is driven by ILC2 cytokine release, and is

critically dependent on IL-33 (Bartemes et al., 2012). Recombinant HpARI co-administration with *Alternaria* allergen abrogated BAL eosinophilia (**Figure 3D**) and lung ILC2 IL-5 (**Figure 3E**) and IL-13 production (**Figure 3F**), 24 h later, again replicating the effects observed with total HES. IL-13-eGFP reporter mice were used to assess ILC2 cytokine responses in the absence of PMA and Ionomycin stimulation, confirming profound suppression of IL-13 reporter expression in ICOS⁺CD90.2⁺IL-33R⁺CD127⁺CD45⁺lineage⁻ ILC2s by HpARI (**Supplementary Figure 3C-E**).

HpARI was administered in a T cell-dependent model of asthma, in which OVA protein is first co-administered with *Alternaria*, and antigen-specific type 2 responses recalled 2 weeks later by challenge with OVA protein alone (McSorley et al., 2014). Again HpARI replicated the suppressive effects of HES on BAL eosinophilia and lung ILC2 responses (**Figure 4A-C**). Furthermore, this suppression led to significantly abrogated lung resistance and compliance at challenge (**Figure 4D, E**), as well as reduced inflammation and mucus production assessed by histological staining (**Figure 4F-H**).

Finally, the role of HpARI in parasite infections was addressed using *Nippostrongylus brasiliensis* infection, a parasite which (unlike *H. polygyrus*) migrates through the lung and leads to early IL-33-dependent type 2 responses (Hung et al., 2013). Similarly to the phenotype seen in an IL-33-deficient mouse, HpARI administration did not affect worm burden at early timepoints, but increased numbers of adult parasites found in the intestinal lumen at day 6 (**Figure 4I-J**). This suppression of parasite rejection was associated with reduced BAL eosinophilia, reaching significance at day 6 (**Figure 4K**). Thus, HpARI

222 abrogates parasite-induced, IL-33-dependent type 2 immune responses,
223 abrogating parasite ejection.

224 *HpARI binding to IL-33*

225 We hypothesised that HpARI could act by binding directly to IL-33. To
226 investigate this, we incubated Myc-tagged HpARI with murine lung cell
227 homogenates, and immunoprecipitated with anti-c-Myc antibody bound to
228 protein G-coated beads. HpARI immunoprecipitated a clear band at ~18 kDa in
229 Myc-tagged complexes eluted from anti-c-Myc-coated, but not isotype control-
230 coated beads, as revealed by anti-IL-33 Western blotting (**Figure 5A**). Unbound
231 material (supernatants from co-immunoprecipitation) showed undetectable or
232 very faint bands for IL-33 under these conditions, reflecting the manner in which
233 immunoprecipitation concentrates ligand sufficiently for detection. No band
234 could be detected for full-length IL-33 (30 kDa) in these experiments (data not
235 shown).

236 Despite human and murine IL-33 sharing only 52% amino acid identity, we
237 found that human IL-33 also co-immunoprecipitates with HpARI after incubation
238 with human lung homogenates, seen as an ~18 kDa band corresponding to
239 mature human IL-33 (**Figure 5B**). In this case, unbound human IL-33 could be
240 detected in supernatants from co-immunoprecipitation or control conditions,
241 also at ~18 kDa.

242 To biochemically characterise the binding of human and mouse IL-33 with
243 HpARI, we assessed the interactions between these proteins by surface plasmon

resonance (SPR) (**Figure 5C-D**). The equilibrium dissociation constant (K_d) of HpARI for murine IL-33 is 0.56 ± 0.1 nM, and 260 ± 13 nM for human IL-33.

Oxidation of IL-33

Recently, it was shown that IL-33 is released in an active reduced form, which is quickly oxidized (<4 h after release) and inactivated under physiological conditions (Cohen et al., 2015). Commercially-available IL-33 ELISA kits do not differentiate between the reduced and oxidized forms. Therefore we decided to investigate whether HpARI preferentially bound to reduced or oxidized IL-33.

To attain a source of oxidized and reduced IL-33, we subjected lung cells to freeze and thaw-mediated necrosis, harvested IL-33-containing supernatants immediately post-thaw, and incubated these at 37°C for 1-4 h to oxidize IL-33 (Cohen et al., 2015). When HpARI was added to supernatants directly post-thaw, or up to 2 h later, it was able to significantly reduce the IL-33 signal as measured by ELISA, whereas by 4 h post-thaw, no effect of HpARI could be seen (**Figure 5E and Supplementary Figure 4A**). Therefore we hypothesized that HpARI binds only to active (reduced) IL-33.

HpARI co-immunoprecipitation experiments were then repeated with either untreated recombinant murine IL-33 (rmIL-33) or rmIL-33 which had been oxidized by incubation for 24 h at 37°C in tissue culture medium. Eluted complexes were run on non-reducing SDS-PAGE gels to distinguish reduced and oxidized IL-33 by their differential migration under non-reducing conditions, the more compact oxidized form migrating more rapidly (Cohen et al., 2015). A strong bias for binding of HpARI to the reduced form could be seen, with

unbound supernatants containing the oxidized form, while no unbound reduced IL-33 could be detected (**Figure 5F**).

Co-immunoprecipitation was repeated with recombinant human IL-33 (rhIL-33), either untreated or oxidized under the same conditions as applied to murine IL-33. Similarly to murine IL-33, rhIL-33 could only be bound by HpARI in its reduced, active form, with oxidation of IL-33 abolishing its ability to be co-precipitated (**Figure 5G**).

Finally, we ensured that the binding of HpARI is specific to IL-33, by binding studies with the closely-related IL-1 family cytokine IL-1 α . No binding of HpARI to IL-1 α could be detected, either by co-immunoprecipitation (**Figure 5H**), or by SPR (**Supplementary Figure 4B**). Thus, HpARI specifically and with high affinity, binds to the active, reduced form of IL-33.

HpARI prevents binding of active IL-33 to the IL-33 receptor.

To investigate whether HpARI binding IL-33 consequently affected downstream responses to IL-33, we investigated the binding of IL-33 to its receptor ST2. Recombinant mL-33 was incubated alone or with HpARI, then immunoprecipitation was carried out using an ST2-Fc fusion protein bound to protein G-coated magnetic beads. The presence of HpARI completely blocked immunoprecipitation of rmIL-33 by ST2-Fc (**Figure 6A**), implying that HpARI prevents IL-33 from binding to its receptor.

Furthermore, when rmIL-33 was administered intranasally to mice, IL-33-mediated ILC2 activation (measured by IL-5 and IL-13 production) was effectively ablated by HpARI co-administration (**Figure 6B-C**). Thus HpARI,

through binding to IL-33, can prevent the activation of ILC2s through ST2 ligation.

HpARI inhibits release of IL-33

As HpARI directly binds IL-33, it could also interfere with detection of the cytokine by ELISA through masking epitopes bound by assay antibodies. This could affect our early screening results, (**Figures 1-3**) as these are largely dependent on ELISA to measure concentrations of IL-33. To investigate the possibility of undetectable HpARI-bound IL-33 in BAL supernatants, IL-33 was measured by both ELISA and western blot, as the latter reduces, denatures and dissociates protein complexes. Mice were treated with *Alternaria* allergen and BAL taken 15 min later (at which timepoint the majority of IL-33 released is active and reduced (Cohen et al., 2015)), HpARI coadministration ablated the IL-33 signal by ELISA (**Figure 6D**), and significantly inhibited (but did not ablate) the IL-33 signal by western blot (**Figure 6E**), implying that although HpARI binding interferes with IL-33 detection by ELISA, IL-33 release is indeed diminished with HpARI administration. In contrast, HpARI could not affect the release of HMGB1, another nuclear-localised alarmin cytokine released on necrosis, (**Supplementary Figure 4C**), demonstrating that the effects of HpARI are specific to IL-33.

To translate these results to human biology, human lung explants were cultured for 1 h with HpARI, a system and timepoint in which lung explants spontaneously release reduced (active) human IL-33 (Cohen et al., 2015). Similarly to the murine system, a reduction in IL-33 signal was seen with HpARI coadministration, as measured by both ELISA and western blot (**Figure 6F, G**).

Furthermore, HpARI was administered with *Alternaria* to human IL-33 transgenic mice (Cohen et al., 2015), where it again suppressed human IL-33 release into the BAL (**Figure 6H, I**). Thus, HpARI reduces the release of both mouse and human IL-33.

Immunofluorescent localization of HpARI

To further investigate the mechanism of action of HpARI, we utilised the CMT-64 mouse lung epithelial carcinoma cell line, which we found stores high amounts of IL-33 in the nucleus (**Supp Figure 5A**). Similarly to lung cells cultured *in vitro*, IL-33 is released from freeze-thawed CMT-64 cells, and this response is suppressed by HpARI (**Supp Figure 5B**). We then produced an HpARI_mCherry fusion protein, allowing fluorescent localization of HpARI binding, while retaining IL-33-suppressive activity (**Supp Figure 5C**).

Although we found no HpARI_mCherry staining of live CMT-64 cells, binding was evident in freeze-thaw treated necrotic cells (**Figure 7A**), where it bound in the nucleus (**Figure 7B**). Surprisingly, we found HpARI_mCherry binds the nucleus independently of IL-33 expression, as similar staining could be seen in HEK293 cells (**Figure 7C**), from which no IL-33 could be detected (data not shown). As binding of HpARI in the nucleus of CMT-64 or HEK293 cells was ablated by addition of DNase I (**Figure 7C**), we hypothesised that HpARI binds directly to DNA in the nucleus of necrotic epithelial cells.

In vivo, DNase co-administration with *Alternaria* allergen abrogated HpARI suppression of IL-33 as measured by western blot, but not by ELISA, in the latter case presumably due to steric hindrance of ELISA antibodies on released HpARI-

bound IL-33 (**Figure 7D, E**). We conclude that dual binding of DNA and IL-33 by HpARI results in retention of IL-33 within the necrotic cell nucleus, conferring a tethering function on HpARI in addition to its ability to block IL-33 in the fluid phase.

Binding of DNA by HpARI was confirmed using a gel shift assay, in which addition of HpARI retarded the migration of linear plasmid DNA through an agarose gel in a concentration-dependent manner (**Figure 7F**), and by immunoprecipitation of plasmid DNA by HpARI (**Supp Fig 5D**). We hypothesised that HpARI could bind DNA through electrostatic interactions, as shown for other CCP module-containing proteins (Sjoberg et al., 2007; Trouw et al., 2005). When the isoelectric point (pI) of each of the three CCP domains of HpARI were calculated, CCP2 and CCP3 were found to be relatively acidic (pI 6.32 and 5.34 respectively), while CCP1 was strongly basic (pI 9.79). Indeed, an electrostatic surface representation of our 3-D model of CCP1 (**Supp Fig 5E**), reveals clusters of solvent-exposed positively charged residues that could serve as a binding site for oppositely-charged (acidic) DNA. We produced truncated versions of HpARI, either encoding CCP1/2 or CCP2/3. As predicted, we found that only the CCP1/2 truncation caused a shift in DNA migration (**Figure 7F**), supporting a role for CCP1 in binding to DNA.

In vivo, only the CCP1/2 HpARI truncation could inhibit the release of IL-33 as measured by western blot, while CCP2/3 actually increased total quantities of IL-33 detected in the BAL (**Figure 7G**). Both constructs suppressed IL-33 detection by ELISA (**Figure 7H**), indicating they could both bind IL-33 and inhibit binding of ELISA antibodies. Therefore we propose that CCP2/3 does not inhibit IL-33

361 release but instead binds it in solution, prevent it from being degraded or taken
362 up via its receptor. This data supports a model by which HpARI binds to IL-33
363 through its CCP2 domain, and to DNA through its CCP1 domain, tethering IL-33
364 within the necrotic cell nucleus.

Discussion

IL-33 has emerged as a critical initiator of allergic responses in diseases such as asthma, sparking an array of type 2 reactions in innate lymphoid cells, eosinophils, macrophages and T cells (Liew et al., 2016). Through screening of the secreted products of a helminth parasite we identified HpARI, a CCP module-containing protein which inhibits IL-33 release. Recombinant HpARI is non-cell permeable, and can only gain access to the nucleus of necrotic cells, where it binds directly to IL-33 and nuclear DNA, tethering IL-33 within necrotic cells and preventing binding to the IL-33R, thereby suppressing ILC2 responses and eosinophilia in the lung after *Alternaria* administration.

The primary mechanistic effect of HpARI is to bind IL-33: remarkably this extends from murine to human IL-33. Although the affinity of HpARI for human IL-33 is lower than that of mouse IL-33, this binding is sufficient to prevent human IL-33 release, with a reduced IL-33 signal in human lung explant supernatants when cultured with HpARI, and reduced human IL-33 release in the lungs of human IL-33 transgenic mice. In the mouse, HpARI proved to be highly suppressive *in vivo*, recapitulating and exceeding the effects of total parasite secretions (HES), and able to inhibit IL-33 release even when administered 24 h prior to allergen challenge.

Although it is clear that IL-33 is released at high levels during tissue injury and necrosis, it is presently unclear how IL-33 is secreted during homeostasis (Liew et al., 2016). We showed that HpARI was not able to penetrate intact cells thus, in the absence of cell membrane damage, HpARI would be unable to mediate the nuclear retention of IL-33. HpARI's unique mechanism of action and specificity

provide an interesting tool to investigate the role of IL-33 as an alarmin – preventing the release of IL-33 from necrotic cells while leaving other responses (necrosis, HMGB1 or IL-1 α release) unaffected. Recently, IL-33 production and release by activated mast cells in response to extracellular ATP release was demonstrated in *H. polygyrus* infection (Shimokawa et al., 2017), and extracellular ATP has previously been shown to induce IL-33 release in response to *Alternaria* administration (Kouzaki et al., 2011). These findings may explain the lack of total ablation of IL-33 release with HpARI administration, as some cytokine may be actively secreted by live mast cells, against which the tethering function of HpARI would be inactive, without exposed DNA in a necrotic, lysed cell. In this context, the role of *H. polygyrus* secreted apyrases (Hewitson et al., 2011) - enzymes which degrade extracellular ATP – may have a further role.

Binding to nuclear DNA allows HpARI to hold active IL-33 within the necrotic cell, and ablates allergic sensitisation. Although the affinity for DNA was not determined in this study, evidence from gel shift and co-immunoprecipitation assays, as well as ablation of necrotic nuclear localization and IL-33 tethering function on DNase treatment, strongly supports binding of HpARI to DNA. Truncated HpARI lacking CCP1 has no activity in the gel shift assay and lack IL-33 tethering functionality, and molecular modeling of CCP1 revealed 2 exposed basic patches as putative DNA binding sites. Of note, the mammalian CCP domain-containing proteins C4b-binding protein (C4BP) (Trouw et al., 2005) and complement factor H (Leffler et al., 2010), also bind DNA through basic CCP modules. The importance of IL-33 localization to the nucleus has been shown in transgenic mice lacking the nuclear localization domain of IL-33, which develop

413 lethal eosinophil-dominant multi-organ inflammation (Bessa et al., 2014), and in
414 human endothelial cells, where extracellular IL-33 leads to inflammatory
415 responses, while nuclear IL-33 does not (Gautier et al., 2016).

416 Three predicted CCP modules span the length of mature HpARI. CCP module-
417 containing proteins are present in different phyla including chordates and
418 nematodes, with notable expansion and diversification in parasitic species such
419 as *H. polygyrus* (Hewitson et al., 2013). The functions of CCP modules are diverse,
420 underlining the versatility of this structural scaffold that has evolved to serve
421 many purposes (Kirkitaдзе and Barlow, 2001; Soares and Barlow, 2005; Soares
422 et al., 2005). Of note, no non-host CCP module-containing protein has previously
423 been shown to have immunomodulatory function outside of the complement
424 system, and hence the co-option of this module by a parasite to block a
425 mammalian immunological pathway is remarkable.

426 The suppression of the IL-33 pathway by *H. polygyrus* at the level of the IL-33
427 cytokine (mediated by HpARI) and the IL-33 receptor (mediated by secreted
428 exosomes (Buck et al., 2014)) indicates that this pathway may be critical to
429 persistence of the parasite. Indeed administration of exogenous IL-33 induces
430 expulsion of *H. polygyrus* (Yang et al., 2013), while IL-33R-deficient mice are
431 slow to expel this parasite even when immunized with a vaccine that induces
432 sterile immunity in wild-type mice (Coakley et al., 2017). Similarly, in many
433 helminth infections IL-33 administration can drive immunity, while deficiency of
434 IL-33 or the IL-33 receptor leads to increased parasite load (Maizels and
435 McSorley, 2016). Hence, the ability of *H. polygyrus* to pre-empt the IL-33 alarmin

system is likely to be a pivotal evolutionary adaptation to allow establishment in the mammalian host.

HpARI administration suppressed the eosinophilic response to *N. brasiliensis* infection, leading to reduced ejection of adult parasites from the intestinal lumen, similarly to the phenotype seen in IL-33-deficient animals (Hung et al., 2013). Thus HpARI is capable of suppressing early innate anti-parasite immunity, a role we hypothesise it to play in the early stages of *H. polygyrus* infection where IL-33 is critical for resistance (Shimokawa et al., 2017).

During an *H. polygyrus* infection, larvae penetrate the gut wall, undergo two molts in the subserosal membrane, and emerge back into the lumen of the gut as adults (Maizels et al., 2012). As the parasite penetrates the intestinal wall, it damages epithelial cells which could result in the release of pre-formed IL-33 and induction of a parasite-toxic type 2 immune response. HpARI is secreted by the parasite larvae and adult (Hewitson et al., 2013) and so is well positioned to ablate this IL-33 response.

Recently, IL-33 was implicated in activation of intestinal Foxp3⁺ regulatory T (Treg) cells (Schiering et al., 2014) raising the possibility that HpARI could interfere with Treg cell-mediated suppression. However, in mouse models of asthma, IL-33 signaling to IL-33R⁺Foxp3⁺ Treg cells results in their expression of Th2 cytokines, and abrogation of suppressive ability (Chen et al., 2017). Thus, in asthmatic responses at least, IL-33 appears to have an inflammatory, rather than suppressive effect.

458 In conclusion, we have identified a CCP module-containing protein with the
459 unique ability to selectively bind to IL-33 and DNA within necrotic epithelial
460 cells. This activity potently suppresses the release and the biological activity of
461 IL-33, resulting in suppression of type 2 responses to allergen challenge. IL-33 is
462 a critical mediator in allergic disease, and an important clinical target. HpARI
463 could be a potent agent for prevention of IL-33-mediated pathology, as well as a
464 new tool for manipulation of IL-33 release, leading to better understanding of the
465 IL-33 pathway.

Author Contributions:

MO, FV, ESC, ICS, WFG, MT, AMK, DJS, HH, AG, CE and HJM carried out the experiments. DCS, AMK, TB, MW and ACI carried out bioinformatic and structural analyses. AMK, KJF, JPH and HJM designed and carried out fractionation experiments. WAW provided human tissue. ESC, ICS, SV, AA, JS, RMM and HJM designed the experiments. MO, DCS, ESC, ICS, RMM and HJM wrote the manuscript.

Acknowledgements

HJM is supported by an Asthma UK Fellowship (SPD-2012-172) and a Medical Research Council Confidence in Concept award (MRC/CIC4/03), RMM is supported by the Wellcome Trust through an Investigator Award (Ref 106122) and core funding to the Wellcome Centre for Molecular Parasitology (Ref 104111). The EPPF is supported by the Wellcome Trust Multi-User Equipment grant 101527/Z/13/Z. ESC and ICS are employees of the AstraZeneca Group and have stock / stock options in AstraZeneca. The authors have no additional financial interests. We thank the Lothian NRS Bioresource for supplying human lung material.

References

Bartemes, K.R., Iijima, K., Kobayashi, T., Kephart, G.M., McKenzie, A.N., and Kita, H. (2012). IL-33-responsive lineage- CD25⁺ CD44(hi) lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs. *J Immunol* 188, 1503-1513.

Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., Weissig, H., Shindyalov, I.N., and Bourne, P.E. (2000). The Protein Data Bank. *Nucleic Acids Res* 28, 235-242.

Bessa, J., Meyer, C.A., de Vera Mudry, M.C., Schlicht, S., Smith, S.H., Iglesias, A., and Cote-Sierra, J. (2014). Altered subcellular localization of IL-33 leads to non-resolving lethal inflammation. *J Autoimmun* 55, 33-41.

Blein, S., Ginham, R., Uhrin, D., Smith, B.O., Soares, D.C., Veltel, S., McIlhinney, R.A., White, J.H., and Barlow, P.N. (2004). Structural analysis of the complement control protein (CCP) modules of GABA(B) receptor 1a: only one of the two CCP modules is compactly folded. *J Biol Chem* 279, 48292-48306.

Bonnelykke, K., Matheson, M.C., Pers, T.H., Granell, R., Strachan, D.P., Alves, A.C., Linneberg, A., Curtin, J.A., Warrington, N.M., Standl, M., *et al.* (2013). Meta-analysis of genome-wide association studies identifies ten loci influencing allergic sensitization. *Nat Genet* 45, 902-906.

Bonnelykke, K., Sleiman, P., Nielsen, K., Kreiner-Moller, E., Mercader, J.M., Belgrave, D., den Dekker, H.T., Husby, A., Sevelsted, A., Faura-Tellez, G., *et al.*

506 (2014). A genome-wide association study identifies CDHR3 as a susceptibility
 507 locus for early childhood asthma with severe exacerbations. *Nat Genet* 46, 51-55.

508 Buck, A.H., Coakley, G., Simbari, F., McSorley, H.J., Quintana, J.F., Le Bihan, T.,
 509 Kumar, S., Abreu-Goodger, C., Lear, M., Harcus, Y., *et al.* (2014). Exosomes
 510 secreted by nematode parasites transfer small RNAs to mammalian cells and
 511 modulate innate immunity. *Nat Commun* 5, 5488.

512 Castanhinha, S., Sherburn, R., Walker, S., Gupta, A., Bossley, C.J., Buckley, J.,
 513 Ullmann, N., Grychtol, R., Campbell, G., Maglione, M., *et al.* (2015). Pediatric
 514 severe asthma with fungal sensitization is mediated by steroid-resistant IL-33. *J*
 515 *Allergy Clin Immunol* 136, 312-322 e317.

516 Cayrol, C., and Girard, J.P. (2014). IL-33: an alarmin cytokine with crucial roles in
 517 innate immunity, inflammation and allergy. *Curr Opin Immunol* 31, 31-37.

518 Chen, C.C., Kobayashi, T., Iijima, K., Hsu, F.C., and Kita, H. (2017). IL-33
 519 dysregulates regulatory T cells and impairs established immunologic tolerance
 520 in the lungs. *J Allergy Clin Immunol*.

521 Christianson, C.A., Goplen, N.P., Zafar, I., Irvin, C., Good, J.T., Jr., Rollins, D.R.,
 522 Gorentla, B., Liu, W., Gorska, M.M., Chu, H., *et al.* (2015). Persistence of asthma
 523 requires multiple feedback circuits involving type 2 innate lymphoid cells and IL-
 524 33. *J Allergy Clin Immunol* 136, 59-68 e14.

525 Coakley, G., McCaskill, J.L., Borger, J.G., Simbari, F., Robertson, E., Millar, M.,
 526 Harcus, Y., McSorley, H.J., Maizels, R.M., and Buck, A.H. (2017). Extracellular

527 vesicles from a helminth parasite suppress macrophage activation and constitute
 528 an effective vaccine for protective immunity. *Cell Rep* 19, 1545-1557.

529 Cohen, E.S., Scott, I.C., Majithiya, J.B., Rapley, L., Kemp, B.P., England, E., Rees, D.G.,
 530 Overed-Sayer, C.L., Woods, J., Bond, N.J., *et al.* (2015). Oxidation of the alarmin IL-
 531 33 regulates ST2-dependent inflammation. *Nat Commun* 6, 8327.

532 de Castro, E., Sigrist, C.J., Gattiker, A., Bulliard, V., Langendijk-Genevaux, P.S.,
 533 Gasteiger, E., Bairoch, A., and Hulo, N. (2006). ScanProsite: detection of PROSITE
 534 signature matches and ProRule-associated functional and structural residues in
 535 proteins. *Nucleic Acids Res* 34, W362-365.

536 De Salvo, C., Wang, X.M., Pastorelli, L., Mattioli, B., Omenetti, S., Buela, K.A.,
 537 Chowdhry, S., Garg, R.R., Goodman, W.A., Rodriguez-Palacios, A., *et al.* (2016). IL-
 538 33 Drives Eosinophil Infiltration and Pathogenic Type 2 Helper T-Cell Immune
 539 Responses Leading to Chronic Experimental Ileitis. *Am J Pathol.*

540 Gautier, V., Cayrol, C., Farache, D., Roga, S., Monsarrat, B., Burlet-Schiltz, O.,
 541 Gonzalez de Peredo, A., and Girard, J.P. (2016). Extracellular IL-33 cytokine, but
 542 not endogenous nuclear IL-33, regulates protein expression in endothelial cells.
 543 *Sci Rep* 6, 34255.

544 Hewitson, J.P., Harcus, Y., Murray, J., van Agtmaal, M., Filbey, K.J., Grainger, J.R.,
 545 Bridgett, S., Blaxter, M.L., Ashton, P.D., Ashford, D.A., *et al.* (2011). Proteomic
 546 analysis of secretory products from the model gastrointestinal nematode
 547 *Heligmosomoides polygyrus* reveals dominance of venom allergen-like (VAL)
 548 proteins. *J Proteomics* 74, 1573-1594.

549 Hewitson, J.P., Ivens, A.C., Harcus, Y., Filbey, K.J., McSorley, H.J., Murray, J.,
 550 Bridgett, S., Ashford, D., Dowle, A.A., and Maizels, R.M. (2013). Secretion of
 551 protective antigens by tissue-stage nematode larvae revealed by proteomic
 552 analysis and vaccination-induced sterile immunity. *PLoS Pathog* 9, e1003492.

553 Howe, K.L., Bolt, B.J., Cain, S., Chan, J., Chen, W.J., Davis, P., Done, J., Down, T., Gao,
 554 S., Grove, C., *et al.* (2016). WormBase 2016: expanding to enable helminth
 555 genomic research. *Nucleic Acids Res* 44, D774-780.

556 Hristova, M., Habibovic, A., Veith, C., Janssen-Heininger, Y.M., Dixon, A.E., Geiszt,
 557 M., and van der Vliet, A. (2016). Airway epithelial dual oxidase 1 mediates
 558 allergen-induced IL-33 secretion and activation of type 2 immune responses. *J*
 559 *Allergy Clin Immunol* 137, 1545-1556

560 Hung, L.Y., Lewkowich, I.P., Dawson, L.A., Downey, J., Yang, Y., Smith, D.E., and
 561 Herbert, D.R. (2013). IL-33 drives biphasic IL-13 production for noncanonical
 562 Type 2 immunity against hookworms. *Proc Natl Acad Sci U S A* 110, 282-287.

563 Jackson, D.J., Makrinioti, H., Rana, B.M., Shamji, B.W., Trujillo-Torralbo, M.B.,
 564 Footitt, J., Jerico, D.-R., Telcian, A.G., Nikonova, A., Zhu, J., *et al.* (2014). IL-33-
 565 dependent type 2 inflammation during rhinovirus-induced asthma exacerbations
 566 in vivo. *Am J Respir Crit Care Med* 190, 1373-1382.

567 Johnston, C.J., Robertson, E., Harcus, Y., Grainger, J.R., Coakley, G., Smyth, D.J.,
 568 McSorley, H.J., and Maizels, R. (2015). Cultivation of *Heligmosomoides polygyrus*:
 569 an immunomodulatory nematode parasite and its secreted products. *J Vis Exp*,
 570 e52412.

571 Jordan, M., Schallhorn, A., and Wurm, F.M. (1996). Transfecting mammalian cells:
 572 optimization of critical parameters affecting calcium-phosphate precipitate
 573 formation. *Nucleic Acids Res* 24, 596-601.

574 Kirkitadze, M.D., and Barlow, P.N. (2001). Structure and flexibility of the multiple
 575 domain proteins that regulate complement activation. *Immunol Rev* 180, 146-
 576 161.

577 Kouzaki, H., Iijima, K., Kobayashi, T., O'Grady, S.M., and Kita, H. (2011). The
 578 danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers
 579 IL-33 release and innate Th2-type responses. *J Immunol* 186, 4375-4387.

580 Lawrence, R.A., Gray, C.A., Osborne, J., and Maizels, R.M. (1996). *Nippostrongylus*
 581 *brasiliensis*: cytokine responses and nematode expulsion in normal and IL-4-
 582 deficient mice. *Exp Parasitol* 84, 65-73.

583 Leffler, J., Herbert, A.P., Norstrom, E., Schmidt, C.Q., Barlow, P.N., Blom, A.M., and
 584 Martin, M. (2010). Annexin-II, DNA, and histones serve as factor H ligands on the
 585 surface of apoptotic cells. *J Biol Chem* 285, 3766-3776.

586 Lefrancais, E., and Cayrol, C. (2012). Mechanisms of IL-33 processing and
 587 secretion: differences and similarities between IL-1 family members. *Eur*
 588 *Cytokine Netw* 23, 120-127.

589 Lefrancais, E., Duval, A., Mirey, E., Roga, S., Espinosa, E., Cayrol, C., and Girard, J.P.
 590 (2014). Central domain of IL-33 is cleaved by mast cell proteases for potent
 591 activation of group-2 innate lymphoid cells. *Proc Natl Acad Sci U S A* 111, 15502-
 592 15507.

593 Lefrancais, E., Roga, S., Gautier, V., Gonzalez-de-Peredo, A., Monsarrat, B., Girard,
 594 J.P., and Cayrol, C. (2012). IL-33 is processed into mature bioactive forms by
 595 neutrophil elastase and cathepsin G. *Proc Natl Acad Sci U S A* *109*, 1673-1678.

596 Letunic, I., Doerks, T., and Bork, P. (2015). SMART: recent updates, new
 597 developments and status in 2015. *Nucleic Acids Res* *43*, D257-260.

598 Liew, F.Y., Girard, J.P., and Turnquist, H.R. (2016). Interleukin-33 in health and
 599 disease. *Nat Rev Immunol* *16*, 676-689.

600 Lovell, S.C., Davis, I.W., Arendall, W.B., 3rd, de Bakker, P.I., Word, J.M., Prisant,
 601 M.G., Richardson, J.S., and Richardson, D.C. (2003). Structure validation by C α
 602 geometry: phi,psi and C β deviation. *Proteins* *50*, 437-450.

603 Maizels, R.M., Hewitson, J.P., Murray, J., Harcus, Y.M., Dayer, B., Filbey, K.J.,
 604 Grainger, J.R., McSorley, H.J., Reynolds, L.A., and Smith, K.A. (2012). Immune
 605 modulation and modulators in *Heligmosomoides polygyrus* infection. *Exp*
 606 *Parasitol* *132*, 76-89.

607 Maizels, R.M., and McSorley, H.J. (2016). Regulation of the host immune system
 608 by helminth parasites. *J Allergy Clin Immunol* *138*, 666-675.

609 Makou, E., Mertens, H.D., Maciejewski, M., Soares, D.C., Matis, I., Schmidt, C.Q.,
 610 Herbert, A.P., Svergun, D.I., and Barlow, P.N. (2012). Solution structure of CCP
 611 modules 10-12 illuminates functional architecture of the complement regulator,
 612 factor H. *J Mol Biol* *424*, 295-312.

613 McSorley, H.J., Blair, N.F., Robertson, E., and Maizels, R.M. (2015). Suppression of
 614 OVA-alum induced allergy by *Heligmosomoides polygyrus* products is MyD88-,

615 TRIF-, regulatory T- and B cell-independent, but is associated with reduced
616 innate lymphoid cell activation. *Exp Parasitol* 158, 8-17.

617 McSorley, H.J., Blair, N.F., Smith, K.A., McKenzie, A.N., and Maizels, R.M. (2014).
618 Blockade of IL-33 release and suppression of type 2 innate lymphoid cell
619 responses by helminth secreted products in airway allergy. *Mucosal Immunol* 7,
620 1068-1078.

621 McSorley, H.J., O'Gorman, M.T., Blair, N., Sutherland, T.E., Filbey, K.J., and Maizels,
622 R.M. (2012). Suppression of type 2 immunity and allergic airway inflammation
623 by secreted products of the helminth *Heligmosomoides polygyrus*. *Eur J Immunol*
624 42, 2667-2682.

625 Moffatt, M.F., Gut, I.G., Demenais, F., Strachan, D.P., Bouzigon, E., Heath, S., von
626 Mutius, E., Farrall, M., Lathrop, M., Cookson, W.O., and Consortium, G. (2010). A
627 large-scale, consortium-based genomewide association study of asthma. *N Engl J*
628 *Med* 363, 1211-1221.

629 Morgan, H.P., Mertens, H.D., Guariento, M., Schmidt, C.Q., Soares, D.C., Svergun,
630 D.I., Herbert, A.P., Barlow, P.N., and Hannan, J.P. (2012). Structural analysis of the
631 C-terminal region (modules 18-20) of complement regulator factor H (FH). *PLoS*
632 *One* 7, e32187.

633 Neill, D.R., Wong, S.H., Bellosi, A., Flynn, R.J., Daly, M., Langford, T.K., Bucks, C.,
634 Kane, C.M., Fallon, P.G., Pannell, R., *et al.* (2010). Nuocytes represent a new innate
635 effector leukocyte that mediates type-2 immunity. *Nature* 464, 1367-1370.

636 Prota, A.E., Sage, D.R., Stehle, T., and Fingerioth, J.D. (2002). The crystal structure
 637 of human CD21: Implications for Epstein-Barr virus and C3d binding. *Proc Natl*
 638 *Acad Sci U S A* 99, 10641-10646.

639 Robert, X., and Gouet, P. (2014). Deciphering key features in protein structures
 640 with the new ENDscript server. *Nucleic Acids Res* 42, W320-324.

641 Saglani, S., Lui, S., Ullmann, N., Campbell, G.A., Sherburn, R.T., Mathie, S.A.,
 642 Denney, L., Bossley, C.J., Oates, T., Walker, S.A., *et al.* (2013). IL-33 promotes
 643 airway remodeling in pediatric patients with severe steroid-resistant asthma. *J*
 644 *Allergy Clin Immunol* 132, 676-685 e613.

645 Sali, A., and Blundell, T.L. (1993). Comparative protein modelling by satisfaction
 646 of spatial restraints. *J Mol Biol* 234, 779-815.

647 Saravia, J., You, D., Shrestha, B., Jaligama, S., Siefker, D., Lee, G.I., Harding, J.N.,
 648 Jones, T.L., Rovnaghi, C., Bagga, B., *et al.* (2015). Respiratory Syncytial Virus
 649 Disease Is Mediated by Age-Variable IL-33. *PLoS Pathog* 11, e1005217.

650 Schiering, C., Krausgruber, T., Chomka, A., Frohlich, A., Adelman, K., Wohlfert,
 651 E.A., Pott, J., Griseri, T., Bollrath, J., Hegazy, A.N., *et al.* (2014). The alarmin IL-33
 652 promotes regulatory T-cell function in the intestine. *Nature* 513, 564-568.

653 Shen, M.Y., and Sali, A. (2006). Statistical potential for assessment and prediction
 654 of protein structures. *Protein Sci* 15, 2507-2524.

655 Shimokawa, C., Kanaya, T., Hachisuka, M., Ishiwata, K., Hisaeda, H., Kurashima, Y.,
 656 Kiyono, H., Yoshimoto, T., Kaisho, T., and Ohno, H. (2017). Mast Cells Are Crucial

657 for Induction of Group 2 Innate Lymphoid Cells and Clearance of Helminth
658 Infections. *Immunity* 46, 863-874 e864.

659 Simon, D., Radonjic-Hosli, S., Straumann, A., Yousefi, S., and Simon, H.U. (2015).
660 Active eosinophilic esophagitis is characterized by epithelial barrier defects and
661 eosinophil extracellular trap formation. *Allergy* 70, 443-452.

662 Sjoberg, A.P., Trouw, L.A., Clark, S.J., Sjolander, J., Heinegard, D., Sim, R.B., Day,
663 A.J., and Blom, A.M. (2007). The factor H variant associated with age-related
664 macular degeneration (His-384) and the non-disease-associated form bind
665 differentially to C-reactive protein, fibromodulin, DNA, and necrotic cells. *J Biol*
666 *Chem* 282, 10894-10900.

667 Soares, D.C., and Barlow, P.N. (2005). Complement Control Protein Modules in
668 the Regulators of Complement Activation. In *Structural Biology of the*
669 *Complement System*, D. Morikis, and J.D. Lambris, eds. (Boca Raton: Taylor &
670 Francis), pp. 19-62.

671 Soares, D.C., Gerloff, D.L., Syme, N.R., Coulson, A.F., Parkinson, J., and Barlow, P.N.
672 (2005). Large-scale modelling as a route to multiple surface comparisons of the
673 CCP module family. *Protein Eng Des Sel* 18, 379-388.

674 Soding, J. (2005). Protein homology detection by HMM-HMM comparison.
675 *Bioinformatics* 21, 951-960.

676 Thompson, J.D., Gibson, T.J., Plewniak, F., Jeanmougin, F., and Higgins, D.G.
677 (1997). The CLUSTAL_X windows interface: flexible strategies for multiple

678 sequence alignment aided by quality analysis tools. *Nucleic Acids Res* 25, 4876-
679 4882.

680 Tordesillas, L., Goswami, R., Benede, S., Grishina, G., Dunkin, D., Jarvinen, K.M.,
681 Maleki, S.J., Sampson, H.A., and Berin, M.C. (2014). Skin exposure promotes a
682 Th2-dependent sensitization to peanut allergens. *J Clin Invest* 124, 4965-4975.

683 Trouw, L.A., Nilsson, S.C., Goncalves, I., Landberg, G., and Blom, A.M. (2005). C4b-
684 binding protein binds to necrotic cells and DNA, limiting DNA release and
685 inhibiting complement activation. *J Exp Med* 201, 1937-1948.

686 Yang, Z., Grinchuk, V., Urban, J.F., Jr., Bohl, J., Sun, R., Notari, L., Yan, S.,
687 Ramalingam, T., Keegan, A.D., Wynn, T.A., *et al.* (2013). Macrophages as IL-25/IL-
688 33-responsive cells play an important role in the induction of type 2 immunity.
689 *PLoS One* 8, e59441.

690

691

692

Figure Legends

Figure 1: HES suppression of IL-33

(A) IL-33 levels (ELISA) in supernatants of naive murine lung cells (1×10^5 per well), cultured for 1 h with *Alternaria* (Alt) allergen (200 $\mu\text{g/ml}$) and HES (10 $\mu\text{g/ml}$).

(B) Propidium iodide (PI) and annexin V (AnnV) staining of cells from (A) was used to assess apoptosis (PI-AnnV+) versus necrosis (PI+AnnV+).

(C) IL-33 levels (ELISA) in supernatants of naive murine lung cells, freeze-thawed in the presence of HES.

All data shows SEM of 2-3 replicates, and are representative of 2-3 repeat experiments.

Figure 2: Identification and bioinformatic characterization of HpARI sequence and structure

(A) IL-33 suppression by HES size fractions.

(B) IL-33 suppression by HES charge fractions.

Data in (A) and (B) are percentage suppression of the IL-33 signal compared to *Alternaria*-only control. Dotted rectangles indicate peaks used for selection of candidates.

(C) IL-33 levels (ELISA) in supernatants of naïve murine lung cells, freeze-thawed in the presence of supernatants of HEK293T cells transfected with four candidate genes. Mean and SEM are shown of 3 replicate wells, representative of 3 repeat experiments.

(D) Alignment of HpARI CCP-like modules with complement receptor type 2 CCP2 (CR2-CCP2) and complement factor H CCP10 (FH-CCP10). The putative disulfide bonding pattern (C^I-C^{III}; C^{II}-C^{IV}), conserved tryptophan (W) and structurally-important proline (P), glycine (G) and hydrophobic amino acid residues (h), characteristic of a CCP-module are indicated. Atypical insertions in CCP2/3 (green box), the hypervariable loop (cyan box) and beta-strands (pink arrows) are indicated, based on known CCP secondary structure of CR2-CCP2, as well as three potential N-linked glycosylation sites (light green box).

(E) HpARI domain schematic, with putative disulfide bonding pattern and location of insertions indicated.

(F) Structural models of the three HpARI CCP-like modules.

Figure 3: HpARI suppresses responses to *Alternaria* allergen

(A) IL-33 levels (ELISA) in supernatants of naive mouse lung cells, cultured for 1 h in the presence of *Alternaria* (200 µg/ml) and HES or HpARI.

(B) IL-33 levels (ELISA) in BAL 1h after *Alternaria* allergen administration with HpARI (5 µg) or proteinase K-degraded and heat-treated HpARI (“HpARI (prK)”).

(C) IL-33 levels (ELISA) in BAL 1 h after *Alternaria* allergen administration, with HpARI (5 µg) administered 1, 24, 72 or 168 h prior to *Alternaria* allergen.

(D) BAL eosinophil numbers 24 h after *Alternaria* allergen, HpARI and HES administration.

(E) Lung ILC2 IL-5 staining from mice in (D).

(F) Lung ILC2 IL-13 staining from mice in (D).

All data representative of 2-3 repeat experiments, each with 3-4 replicates/mice per group.

Figure 4: HpARI suppresses responses to *Alternaria* allergen

(A) Day 17 BAL eosinophil numbers after *Alternaria* allergen, OVA protein and HpARI administration on day 0 (sensitisation), and OVA protein alone on days 14, 15 and 16 (challenge).

(B) Lung ILC2 IL-5 production from mice in (A).

(C) Lung ILC2 IL-13 production from mice in (A)

(D) Lung resistance in methacholine challenge from mice treated as in (A)

(E) Lung compliance in methacholine challenge from mice treated as in (A)

(F) H&E- (top panels) and PAS-stained (bottom panels) lung sections from mice treated as in (A). Scale bars indicate 100 μ m.

(G) H&E scoring of sections from mice treated as in (A).

(H) PAS scoring of sections from mice treated as in (A)

Alternaria model data representative of 2-3 repeat experiments, each with 4-6 mice per group.

(I) Mice were subcutaneously infected with *N. brasiliensis*, and HpARI administered intranasally on days 0, 1 and 2 of infection. Lung larvae were counted 3 days after infection.

(J) Day 6 intestinal *N. brasiliensis* worms from mice treated as in (I).

(K) Day 3 and day 6 BAL eosinophil numbers from mice treated as in (I).

Figure 5: HpARI binds active murine and human IL-33

(A) Murine IL-33 western blot (non-reducing) of HpARI immunoprecipitation of mouse lung homogenates, using anti-c-Myc antibody, or MOPC isotype control (iso).

(B) Human IL-33 western blot (non-reducing) of HpARI immunoprecipitation of human lung homogenates, as in (A).

(C) Characterization of the interaction of mouse IL-33 (mIL-33) with HpARI by surface plasmon resonance (SPR - BIAcore T200). Reference corrected single kinetic titration SPR binding curves (black), and a globally fitted 1:1 kinetic binding model (grey).

(D) Characterisation by SPR of the interaction of human IL-33 (hIL-33) with HpARI, as in (C).

(E) IL-33 levels (ELISA) in supernatants of freeze-thawed murine lung cells, incubated at 37°C for 0, 1, 2 or 4 h, before addition of 1 µg/ml HpARI, and a further incubation for 1 h at 37°C.

(F) Untreated or oxidised recombinant murine IL-33 immunoprecipitated with HpARI as in (A).

(G) Untreated or oxidised recombinant human IL-33 immunoprecipitated with HpARI as in (B)

(H) Immunoprecipitation experiments repeated with recombinant murine IL-1α, and probed with anti-murine IL-1α.

Arrows indicate specific IL-33 or IL-1α bands, and IL-33 reduced (“red”) or oxidised (“ox”) bands. All data representative of at least 2 independent repeats.

Figure 6: HpARI blocks IL-33-ST2 interactions and inhibits IL-33 release

(A) IL-33 western blot (non-reducing) of ST2-Fc fusion protein immunoprecipitation of recombinant murine IL-33 in the presence or absence of HpARI.

(B) Lung ILC2 IL-5 production 24 h after intranasal administration of recombinant murine IL-33 (200 ng/mouse) with 5 µg HpARI.

(C) Lung ILC2 IL-5 production from mice described in (B).

(D) Murine IL-33 levels (ELISA) in BAL 15 min after *Alternaria* allergen and HpARI were intranasally administered.

(E) Murine IL-33 western blot (~20 kDa band and densitometry analysis) of BAL from mice described in (D).

(F) Human IL-33 levels (ELISA) in supernatants of human lung explants cultured for 1 h with HpARI.

(G) Human IL-33 western blot (~20 kDa band and densitometry analysis) of supernatants from human lung explants cultures described in (F).

(H) Human IL-33 levels (ELISA) in BAL fluid of human IL-33-transgenic mice, 30 min after *Alternaria* allergen and HpARI intranasally administration.

(I) Human IL-33 western blot (~20 kDa band and densitometry analysis) of BAL from human IL-33-transgenic mice described in (H).

Mouse data (A-E, H-I) representative of 2-4 repeat experiments, each with 3-4 mice per group. Human data (C, D) shows 5 independent subjects.

Figure 7: HpARI binds nuclear DNA, tethering IL-33 within necrotic cells

(A) Live (top panels) or freeze-thawed (bottom panels) CMT-64 cells were incubated for 1 h at 37°C with 5 µg/ml HpARI_mCherry.

(B) HpARI_mCherry-stained freeze-thawed CMT-64 cells, with Hoechst 33342 nuclear co-stain.

(C) Freeze-thawed CMT-64 or HEK293T cells were stained with HpARI_mCherry with 100 U/ml DNase I.

(D) Murine IL-33 western blot densitometry of BAL taken 15 min after *Alternaria* allergen, HpARI and DNase (100 U) intranasal administration.

(E) Murine IL-33 levels (ELISA) IL-33 in BAL fluid from mice described in (D)

(F) Gel shift assay of linearised plasmid DNA, incubated with 100, 50 or 25 pmol of HpARI, CCP1/2 or CCP2/3 truncated proteins..

(G) Murine IL-33 western blot densitometry of BAL taken 15 min after *Alternaria* allergen, HpARI or CCP1/2 or CCP2/3 HpARI truncated proteins intranasal administration.

(H) Murine IL-33 levels (ELISA) in BAL from mice described in (G).

All data representative of at least 2 repeat experiments. Data in (D) and (E) shows mean and SEM of 3 pooled experiments, data log-transformed for statistical analysis to equalize variances. Scale bars = 100 µm.

CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and request for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Henry McSorley (henry.mcsorley@ed.ac.uk).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Mice

BALB/cOlaHsd, C57BL/6JOlaHsd, IL-13-eGFP (C57BL/6 background) (Neill et al., 2010) and ST2-deficient (BALB/c background, kindly provided by Dr Andrew McKenzie, MRC Laboratory of Molecular Biology, Cambridge) mice, male or female (single sex within an experiment), 6-10 weeks old, were bred in-house at the University of Edinburgh. hIL-33^{+/+}, mIL-33^{-/-} (humanised IL-33) transgenic mice (BALB/c background) (Cohen et al., 2015) were bred in-house at the Babraham Institute, Cambridge. All mice were accommodated, and procedures performed under UK Home Office licenses with institutional oversight performed by qualified veterinarians.

Human Tissue Samples

Non-cancerous adjacent tissue from lung cancer patients was collected by Lothian NRS Bioresource, and cultured as previously described (Cohen et al., 2015). The study was approved by Lothian NRS Bioresource (15/ES/0094) and tissue was donated with the informed consent of patients.

METHOD DETAILS

Parasite lifecycles, infection and HES preparation

The life cycle of *H. polygyrus bakeri* was maintained, and HES products prepared, as previously described (Johnston et al., 2015). The life cycle of *N. brasiliensis* was maintained in Sprague-Dawley rats as previously described (Lawrence et al., 1996), and infective L3 larvae were prepared from 1-3 week rat fecal cultures. BALB/c mice were subcutaneously infected with 500 L3 *N. brasiliensis* larvae. At day 3 post-infection, larvae were counted in the bronchoalveolar lavage and in lung tissue, by dicing lungs and placing them in a cheese-cloth bag in a 50 ml tube containing PBS at 37°C for at least 3 h. Day 3 lung counts reflect a sum of the BAL and lung larval counts for each animal. At day 6 intestinal worms were recovered from intestinal tissue using an adapted Baermann apparatus.

Reagents:

Alternaria alternata extract (Greer XPM1D3A25) was resuspended in PBS, filter sterilized and concentration assessed by BCA assay (Pierce). CMT-64 cells (ECACC 10032301) and HEK293T cells (ATCC CRL-3216) were maintained by serial passage in DMEM medium containing 10% fetal bovine serum, 2 mM L-glutamine and 1 μ g ml⁻¹ penicillin/streptomycin. Human and murine IL-33 and murine IL-1 α were purchased from BioLegend.

In vitro IL-33 release assay:

HES, candidate proteins or HpARI were cultured with total murine lung cells prepared by Liberase/DNase digestion of naïve mouse lungs or CMT-64 cells for 1 h at 37°C, 5% CO₂, with *Alternaria* allergen (200 μ g ml⁻¹), or were frozen on dry ice, and thawed at 37°C.

Preparation of murine lung single cell suspension:

Single-cell suspensions of naïve murine lung tissue were prepared by digesting in 2 U ml⁻¹ liberase TL (Roche, Burgess Hill, UK) and 80 U ml⁻¹ DNase (Life Technologies, Paisley, UK) at 37°C with agitation for 35 min. Digested tissue was macerated through a 70 µm cell strainer (BD Biosciences), treated with red blood cells lysis buffer (Sigma), and live cells counted on a haemocytometer, excluding dead cells by trypan blue staining.

Cytokine measurement:

R&D Systems Duoset kits were used to measure human and murine IL-33 by ELISA, while western blotting was carried out using polyclonal goat anti-mouse IL-33, goat anti-human IL-33 or goat anti-mouse IL-1α (R&D Systems) with a rabbit anti-goat IgG HRP secondary antibody (Thermo Fisher), and detected using WesternSure Premium reagent (Licor).

Fractionation and mass spectrometry:

HES was separated into 1 ml fractions by size exclusion chromatography using a Superdex 200 10/300 GL column, or by anion exchange chromatography using a MonoQ 5/50 GL column (GE Healthcare) in a 40 column volume gradient from 20 mM TrisHCl pH 8 (start buffer) to a maximum of 30 % 20 mM TrisHCl + 1 M NaCl pH 8 (elution buffer). All fractions were trypsinized and analyzed by LC MS/MS on an on-line system consisting of a capillary-pump Agilent 1200 HPLC system (Agilent, UK) coupled to an Orbitrap XL mass spectrometer (Thermo Scientific) as previously described (Hewitson et al., 2011; Hewitson et al., 2013). LC MS/MS data was analyzed using Mascot (v2.4, Matrix Science) and searched against an improved in-house BLASTx annotated database obtained by 454 sequencing of *H. polygyrus* adults, with additional full length *H. polygyrus* sequences from NCBI, WormBase ParaSite (Howe et al., 2016) and our own

Sanger sequencing (Harcus Y. et al, manuscript in preparation). Peptides identified were ranked by Mascot protein score, with a minimum cutoff score of 20, with a significance threshold of $p < 0.05$. Protein abundance was estimated by emPAI (exponentially modified protein abundance index).

Protein expression and purification

Candidate genes were selected by comparison of emPAI and IL-33-suppression profiles in all fractions (**Supplementary Figures 1-2**). Candidate genes A-D (**Figure 2A**, respectively Hp_I10793_IG03481_L623, Hp_I15874_IG07818_L1106, Hp_I46029_IG37973_L313 and Hp_I08176_IG02172_L1157 transcripts) were codon optimised for *Homo sapiens* and gene synthesised (GeneArt, Thermo Fisher) with 5' AscI and 3' NotI restriction enzyme sites. CCP1/2 (amino acids 17-165) and CCP2/3 (amino acids 80-251) constructs were created using PCR of codon-optimised HpARI, and primers which added a NotI site 3' of the CCP2 module (5'GCGGCCGCTTGGGGCACACGCCAG3', primes reverse of LGVCPK amino acid sequence, for CCP1/2 construct), or an AscI site 5' of the CCP2 module (5' 5'GGCGCGCCGGCTGCAAGGGCATCCTG3', primes GCKGIL amino acid sequence, for CCP2/3 construct), combined with vector-specific T7 (5' of insert) and BGH (3' of insert) primers. The HpARI_mCherry fusion protein was created by cloning in a codon-optimised gene-synthesised mCherry sequence (ANO45948.1) at the C-terminus of the HpARI protein, using an mCherry 5' NotI site and a 3' ApaI site. These constructs were sub-cloned into the pSecTAG2A expression vector (Thermo Fisher), using AscI, NotI-HF and Apa-1 restriction enzyme digestion (New England Biolabs), followed by T4 DNA ligation (Thermo Fisher).

JM109 cells were transformed with ligated constructs and plasmids were midiprepmed using the PureLink HiPure midiprep kit (Thermo Fisher) according to manufacturers instructions, and Sanger sequenced. Plasmid constructs were transfected into HEK293T cells using the calcium phosphate technique (Jordan et al., 1996), using 15 µg plasmid DNA per 100 mm tissue culture dish of HEK293T cells at 20% confluency. Stable cell lines were maintained using Zeocin (Thermo Fisher) selection in DMEM medium containing 10% fetal bovine serum, 2 mM L-glutamine and 1 µg ml⁻¹ Penicillin/Streptomycin.

Resulting expressed proteins secreted to the medium contained C-terminal myc and 6-His tags. For large scale expression of constructs, transfected cells were transferred to 293 SFM II media (Thermo Fisher) and protein purified from supernatant by nickel affinity chromatography using HiTrap chelating HP columns (GE Healthcare), eluting bound proteins using an imidazole gradient. Fractions containing pure expressed protein were pooled, dialysed into PBS, sterile filtered and concentration assessed by absorbance at 280 nm, corrected by calculated extinction coefficient.

Purified HpARI had an endotoxin content of below 0.5 U LPS per µg protein, as measured by the Limulus Amoebocyte Lysate assay (Lonza).

Bioinformatics characterization and modeling:

Domain identification and assignment were undertaken using a combination of SMART (Letunic et al., 2015), an HHPred search against the pdb70 database (accessed March 2016) (Berman et al., 2000; Soding, 2005), and refined manually based upon positioning of the four Cysteine residues that typify CCP module sequences (Soares et al., 2005). PROSITE (de Castro et al., 2006) was

used for short motif searches. ESPript v3 (Robert and Gouet, 2014) was used for alignment figure preparation.

The three predicted HpARI CCP module sequences were modeled based upon their top ranked CCP module template structure 'hits' as suggested by HHPred. HpARI-CCP1 was modeled based upon CR2-CCP2 (PDB ID: 1LY2) (Prota et al., 2002) (after a manual switch of Leu⁶⁹ with Trp⁶⁹ to help identify this CCP module using HHPred; note Leu/Trp substitutions exist in other experimentally-determined CCP module structures such as complement Factor H CCP10 and CCP20 (Makou et al., 2012; Morgan et al., 2012); HpARI-CCP2 on CSMD1-CCP3 (PDB ID: 2EHF) (RIKEN Structural Genomics/Proteomics Initiative); HpARI-CCP3 on GABABR1 α -CCP2 (PDB ID: 1SRZ) (Blein et al., 2004). The target-template alignment in each case was based upon the initial HHPred alignment, then extended to include the first Cysteine residue in each domain, realigned using ClustalX (Thompson et al., 1997), and finally subjected to manual editing to optimally position known consensus residues, secondary structure elements and gaps (Soares et al., 2005). Note, an alternative alignment for the atypical insertion in CCP3 is possible where it can be accommodated after the hypervariable loop (not shown). A total of 100 models for each CCP module were built using Modeller v9.12 (Sali and Blundell, 1993), and the model with the lowest DOPE (Shen and Sali, 2006) energy score selected as the representative model in each case and evaluated for valid stereochemistry (Lovell et al., 2003). Electrostatic surface potential was calculated using APBS (Baker et al, 2001). PyMOL (<http://www.pymol.org/>; Schrödinger, LLC.) was used for visualization, and figure preparation.

Alternaria models

Alternaria models, lung cell preparation, flow cytometry and lung histology were carried out as previously described (McSorley et al., 2014). *Alternaria* allergen (25 µg) was administered intranasally with 20 µg OVA protein (Sigma) and HpARI (10 µg). In some experiments, the OVA-specific response was recalled by daily intranasal administration of 20 µg OVA protein on days 14, 15 and 16. Mice were culled 15 min, 1 h, 24 h or 17 days after the initial administration, as indicated. Bronchoalveolar lavage was collected (4 lavages with 0.5 ml ice-cold PBS), followed by lung dissection for tissue digestion and single cell preparation (see below), or lungs were inflated with 10% neutral buffered formalin for histology. Formalin-fixed lungs were transferred into 70% ethanol 24 h after collection, paraffin, embedded and sectioned (5 µm), prior to staining with haematoxylin and eosin (H&E) or Periodic Acid Schiff (PAS). H&E and PAS-stained sections were scored blindly according to the following criteria: H&E stain at 200X magnification on an increasing severity score of 1–4 in both the peri-vascular and peri-bronchiolar compartments (1 = <5, 2 = 5-20, 3 = 20-100, 4 = >100 cells), giving an average overall score of 5-10 fields of view per section. PAS stained sections were scored at 100X magnification, on percentage of mucous-positive epithelial cells (1 = <1%, 2 = 1-20%, 3 = 20-50%, 4 = 50-100%), of 5-10 fields of view per section.

Measurement of airway hyperresponsiveness

A Flexivent system (Scireq, Montreal, Canada) was used to measure dynamic resistance and compliance. Mice were anaesthetised with intraperitoneal ketamine 200 mg/kg and pentobarbitone (50 mg/kg), tracheotomised and mechanically ventilated. Lung resistance and compliance were measured in response to nebulised methacholine (Sigma).

1001 ***Immunoprecipitation:***

1002 Protein G dynabeads (Thermo Fisher) were coated with 5 µg anti-c-Myc (clone
1003 Myc.A7, Thermo Fisher), MOPC (IgG1 isotype control antibody) or ST2-Fc fusion
1004 protein (Biolegend), and washed on a DynaMag-2 magnet with PBS containing
1005 0.02% Tween 20. These were then used to immunoprecipitate HpARI-IL-33
1006 complexes, following manufacturer's instructions.

1007 Where human or mouse lung homogenates were used, these were prepared by
1008 homogenizing (Tissuelyser II, QIAGEN) one lung lobe (mouse) in 1 ml PBS, or
1009 400 mg human lung tissue in 1 ml PBS. Lung homogenates (100 µl) or 100 ng
1010 human or murine recombinant IL-33 (Biolegend) were then mixed with 1 µg
1011 HpARI in PBS containing 100 µg/ml OVA protein, and incubated for 30 min at
1012 37°C. Complexes were then added to coated dynabeads, incubated for 10 min at
1013 room temperature, and unbound material collected. Bound material on beads
1014 was washed 3 times in PBS+0.02% PBS on a DynaMag-2 magnet, before
1015 transferring to a fresh tube and eluting bound complexes using 50 mM glycine
1016 pH 2.8 (non-denaturing), before neutralising in 1M Tris buffer, pH 8. Eluted
1017 proteins and unbound supernatants were ran on 4-12% SDS-PAGE gels (Thermo
1018 Fisher) under non-reducing conditions, and transferred to nitrocellulose
1019 membranes for western blotting.

1020 ***Surface Plasmon Resonance (SPR)***

1021 SPR measurements were performed using a BIAcore T200 instrument (GE
1022 Healthcare). Ni²⁺-nitrilotriacetic acid (NTA) sensor chips were purchased from
1023 GE Healthcare. HpARI was immobilised on an NTA sensor surface to 400 RU,
1024 which gave essential zero baseline drift over the time course of the experiments
1025 performed: the apparent k_{-} for the His-tagged HpARI Ni²⁺-NTA surfaces was

significantly slower than the complex being studied $\sim 5 \times 10^{-5} \text{ s}^{-1}$ for HpARI-Ni-NTA *vs* $\sim 14\text{-}400 \times 10^{-5} \text{ s}^{-1}$ for HpARI-IL-33, therefore short cycle (400-600 s total run times) single kinetic analysis could be reliably performed. Following Ni^{2+} priming (30 sec injection of $500 \mu\text{M}$ NiCl_2 at $5 \mu\text{L}\cdot\text{min}^{-1}$) 50 nM HpARI, in 10 mM NaH_2PO_4 , pH 7.5; 150 mM NaCl ; $50 \mu\text{M}$ EDTA ; 0.05% surfactant P20, was captured *via* the 6-His tag by injection for 15 seconds, at $30 \mu\text{L}\cdot\text{min}^{-1}$. Surface regeneration between cycles and/or experiments was performed by dissociating any immobilised His-tagged protein or complex by a 90 s injection of 350 mM EDTA , in 10 mM NaH_2PO_4 , pH 7.5; 150 mM NaCl ; 0.05% surfactant P20 followed by a 30 s injection of 50 mM NaOH at the same flow rate.

SPR kinetic titration binding experiments were performed at 25°C . Three-fold dilution series of mL-33 (6.2 nM to 167 nM) or hIL-33 ($0.062 \mu\text{M}$ to $1.67 \mu\text{M}$), were injected over the sensor surface, in 10 mM NaH_2PO_4 , pH 7.5; 150 mM NaCl ; $50 \mu\text{M}$ EDTA ; 0.05% surfactant P20, at $30 \mu\text{L}\cdot\text{min}^{-1}$ for 30 s followed by a 60 s dissociation phase. The same concentration series of mL-33/hIL-33 were ran over Ni^{2+} -charged NTA surfaces, and showed no evidence of non-specific interaction of mL-33/hIL-33 interacting with these surfaces. All experiments were performed on Ni^{2+} -charged surfaces following non-specific binding assessment and were double referenced using similar blank surface responses for run-noise corrections. The on- (k_+) and off-rate (k_-) constants and the equilibrium dissociation constant (K_d) were calculated by global fitting all three surfaces simultaneously to a 1:1 interaction model, with mass transport considerations, to the double reference corrected sensorgrams, using analysis software (v.2.01, GE Healthcare) provided with the BIAcore T200 instrument.

Both interactions were extremely well fit by a simple 1:1 interaction model (χ^2 values of 0.457 and 0.395, mL-33 and hIL-33 respectively), with R_{Umax} values close to the theoretical maximum expected for a 1:1 stoichiometric interaction with high specific activity (~ 180 RU; 173 RU and 169.3 RU, mL-33 and hIL-33 respectively) and showed no evidence of mass transport issues.

Human lung explant culture

Approximately 5 g of lung tissue was washed 3 times in PBS and ~0.5 mm² tissue explants prepared using sterilized scissors. Explants were incubated in 400 μ l PBS+0.1% BSA +/- 10 μ g/ml HpARI in wells of a 48-well tissue culture plate (Costar) for 1 h, at 37°C, 5% CO₂. Each condition was performed with 8 replicates for IL-33 measurement by ELISA, and pairs of supernatants were pooled (to make 4 replicates) for IL-33 western blot. After culture, tissue pieces were weighed, and IL-33 levels calculated relative to tissue weight.

Gel shift assay

Linearized Not-HF-cut pSecTAG2A plasmid (10 ng) was mixed with HpARI, CCP1/2 and CCP2/3 proteins, in 10 mM TrisCl, 1 mM EDTA, and incubated for 30 min at 37°C. Complexes were ran on a 0.7% agarose gel and imaged with Gelred (Biotium).

QUANTIFICATION AND STATISTICAL ANALYSIS

All data was analyzed using Prism (Graphpad Software Inc.). Where two groups were compared, Student's t-test was used, where there were 3 or more groups, one-way ANOVA with a Bonferroni's post test was used, and for comparing groups at multiple timepoints two-way ANOVA with a Sidak's post test was used.

1075 **** = $p < 0.0001$, *** = $p < 0.001$, ** = $p < 0.01$, * = $p < 0.05$, N.S. = Not Significant

1076 ($p > 0.05$).

1077

1078

1079

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Anti-mouse CD3 (clone 145-2C11)	Biolegend	100306
Anti-mouse CD4 (clone RM4.5)	Biolegend	100566
Anti-mouse CD5 (clone 53-7.3)	Biolegend	100606
Anti-mouse CD11b (clone M1/70)	Biolegend	101224
Anti-mouse CD11c (clone N418)	Biolegend	117312
Anti-mouse CD19 (clone 6D5)	Biolegend	11506
Anti-mouse CD25 (clone PC61)	Biolegend	102038
Anti-mouse CD45 (clone 30-F11)	Biolegend	103128
Anti-mouse CD49b (clone DX5)	eBioscience	11-5971-85
Anti-mouse CD127 (clone A7R34)	Biolegend	135013
Anti-mouse ICOS (clone 15F9)	eBioscience	46-9940-82
Anti-mouse GR1 (clone RB6-8C5)	Biolegend	108406
Anti-mouse IL-5 (clone TRFK5)	Biolegend	504304
Anti-mouse IL-13 (clone eBio13A)	eBioscience	25-7133-82
Anti-mouse Ly6G (clone 1A8)	Biolegend	127616
Anti-mouse SiglecF (clone ES22-10D8)	Miltenyi	130-102-274
Anti-mouse ST2 (clone RMST2-2)	eBioscience	17-9335-82
Anti-mouse TER119 (clone TER-119)	Biolegend	116220
Anti-HMGB-1 rabbit polyclonal	Abcam	Ab18256
Anti-c-myc (clone Myc.A7)	Thermo Fisher Scientific	MA1-21316
Anti-human IL-33 goat polyclonal	R&D Systems	AF3625
Anti-mouse IL-33 goat polyclonal	R&D Systems	AF3626
Anti-mouse IL-1 α	R&D Systems	AF-400-NA
IgG1 isotype control antibody (clone MOPC-21)	Produced in-house	N/A
Bacterial and Virus Strains		
<i>Heligmosomoides polygyrus</i>	(Johnston et al, 2015)	N/A
<i>Nippostrongylus brasiliensis</i>	(Lawrence et al, 1996)	N/A
Biological Samples		
Human lung tissue	Lothian NRS Bioresource	15/ES/0094
Chemicals, Peptides, and Recombinant Proteins		
Recombinant mouse IL-1 α	Biolegend	575002
Recombinant mouse IL-33	Biolegend	580506
Recombinant human IL-33	Biolegend	581806
ST2-Fc	Biolegend	557904
Dynabeads Protein G	Thermo Fisher Scientific	10004D
Proteinase K	Sigma	557904
DNase (protease-free)	Sigma	4536282001
Liberase TL	Sigma	05401020001
Methylcholine chloride	Sigma	A2251
Hoescht 33342	Thermo Fisher Scientific	H3570
Critical Commercial Assays		
Mouse IL-33 DuoSet ELISA	R&D systems	DY3626

Human IL-33 DuoSet ELISA	R&D systems	DY3625B
Annexin V Apoptosis Detection Kit	eBioscience	88-8005-72
Limulus Amoebocyte Lysate assay	Lonza	QCL-1000
Deposited Data		
Experimental Models: Cell Lines		
HEK293T	ATCC	CRL-3216
CMT-64	ECACC	10032301
Experimental Models: Organisms/Strains		
Mouse: IL-13-eGFP (C57BL/6J)	(Neill et al., 2010)	N/A
Mouse: hIL-33 ^{+/+} / mIL-33 ^{-/-} (humanized IL-33) (BALB/c)	(Cohen et al., 2015)	N/A
Oligonucleotides		
Recombinant DNA		
pSecTAG2A plasmid	Thermo Fisher Scientific	V90020
Software and Algorithms		
ClustalX	(Thompson et al., 1997)	www.clustal.org
Mascot v2.4	Matrix Science	www.matrixscience.com
SMART	(Letunic et al., 2015)	smart.embl-heidelberg.de/
HHpred	(Soding, 2005)	toolkit.tuebingen.mpg.de/#/tools/hhpred
Modeller v9.12	(Sali and Blundell, 1993)	salilab.org/modeller/
APBS	(Baker et al, 2001)	www.poissonboltzmann.org/
ESPrpt v3	(Robert and Gouet, 2014)	esprpt.ibcp.fr/
PyMOL	Schrödinger, LLC	www.pymol.org
PROSITE	(de Castro et al., 2006)	prosite.expasy.org/
Protein Data Bank	(Berman et al., 2000)	www.rcsb.org/pdb
Wormbase ParaSite	(Howe et al., 2016)	parasite.wormbase.org/
FlowJo v9.1	Flowjo, LLC	www.flowjo.com/
Prism v7	Graphpad Software	www.graphpad.com/scientific-software/prism/
BIAcore T200 software v2.01	GE Healthcare	N/A
Other		
Superdex 200 10/300 GL	GE Healthcare	17517501
MonoQ 5/50 GL	GE Healthcare	17-5166-01
Series S Sensor Chip NTA	GE Healthcare	BR-1005-32

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6





Figure 7





	Blast hit	Size fraction 11			Charge fraction 25		
		emPAI	Mascot protein score	Rank (of 194) ^a	emPAI	Mascot protein score	Rank (of 262) ^a
Hp_I10793_IG03481_L623	No BLASTX similarities 13330478:13331100 forward	1.35	99	57	0.53	104	77
Hp_I15874_IG07818_L1106	BLASTX similarity to 66.67% ID to CBN-NUC-1 protein [Caenorhabditis brenneri] (376 aa, Accession: gi 341901954 gb EGT57889.1)	1.11	229	19	5.23	786	2
Hp_I46029_IG37973_L313	BLASTX similarity to 55.93% ID to unnamed protein product [Homo sapiens] (304 aa, Accession: gi 189069304 dbj BAG36336.1)	2.01	67	90	0.73	50	163
Hp_I08176_IG02172_L1157	BLASTX similarity to 72.38% ID to PHA domain [Heligmosomoides polygyrus bakeri] (252 aa, Accession: gi 345499002 emb CCC54333.1)	0.13	61	100	1.05	353	18
GSXTT4C07IB13H_length=463	BLASTX similarity to 86.32% ID to venom allergen/ ancylostoma secreted protein-like 1 isoform 4 [Heligmosomoides polygyrus bakeri] (459 aa, Accession: gi 348659354 gb AEP82914.1)	0.53	59	105	2.58	246	1
Hp_I00796_IG00050_L1763	BLASTX similarity to 60.51% ID to metalloprotease 1 precursor [Ancylostoma ceylanicum] (547 aa, Accession: gi 23268453 gb AAN11401.1)	0.37	163	32	0.78	518	3
Hp_I03365_IG00388_L986	BLASTX similarity to 83.05% ID to putative ES protein F7 [Ostertagia ostertagi] (181 aa, Accession: gi 18104159 emb CAD20464.1)	0.2	73	80	3.37	408	14
Hp_I05355_IG00918_L1570	BLASTX similarity to 61.84% ID to astacin-like metalloprotease [Haemonchus contortus] (502 aa, Accession: gi 82653303 emb CAJ43810.1)	0.51	205	20	0.34	137	20
Hp_I07496_IG01832_L2183	BLASTX similarity to 49.47% ID to metalloprotease I [Ostertagia ostertagi] (573 aa, Accession: gi 25005280 emb CAD28559.2)	0.23	184	24	0.52	300	26
Hp_I09193_IG02681_L996	BLASTX similarity to 27.72% ID to Chain A, Calcium-Bound Ac-Asp-7 (206 aa, Accession: gi 383875397 pdb 3S6U A)	0.2	78	72	1.28	312	24
Hp_I09338_IG02753_L893	BLASTX similarity to 69.57% ID to Chain A, Glutathione Transferase-2, Apo Form, From The Nematode Heligmosomoides Polygyrus (206 aa, Accession: gi 51247756 pdb 1TW9 A)	0.36	81	60	0.23	90	59
Hp_I12757_IG04701_L2227	BLASTX similarity to 69.27% ID to hypothetical protein CAEBREN_19315 [Caenorhabditis brenneri] (713 aa, Accession: gi 341886485 gb EGT42420.1)	0.9	321	9	0.29	119	67
Hp_I12915_IG04859_L2071	BLASTX similarity to 74.56% ID to hypothetical protein CAEBREN_01953 [Caenorhabditis brenneri] (594 aa, Accession: gi 341889762 gb EGT45697.1)	0.25	146	39	0.43	190	39
Hp_I13075_IG05019_L1949	BLASTX similarity to 25.30% ID to GD14343 [Drosophila simulans] (699 aa, Accession: gi 195589672 ref XP_002084573.1)	0.71	317	10	1.15	478	8
Hp_I13426_IG05370_L1731	BLASTX similarity to 61.51% ID to hexokinase [Haemonchus contortus] (485 aa, Accession: gi 4583627 emb CAB40412.1)	1.51	564	4	0.81	409	13
Hp_I13832_IG05776_L1555	BLASTX similarity to 59.25% ID to metalloprotease III [Ostertagia ostertagi] (507 aa, Accession: gi 21425408 emb CAD19995.2)	0.6	152	38	0.9	340	20
Hp_I14648_IG06592_L1319	No BLASTX similarities 18271778:18273096 forward	1.67	280	15	0.75	180	41
Hp_I14766_IG06710_L1294	BLASTX similarity to 42.09% ID to Hyaluronidase-1, partial [Ascaris suum] (439 aa, Accession: gi 324516157 gb ADY46439.1)	0.15	57	109	0.42	96	86
Hp_I15012_IG06956_L1244	BLASTX similarity to 71.51% ID to hypothetical protein CRE_02222 [Caenorhabditis remanei] (368 aa, Accession: gi 308509410 ref XP_003116888.1)	0.56	167	21	0.25	138	57
Hp_I15720_IG07664_L1128	BLASTX similarity to 83.79% ID to hypothetical protein CRE_30062 [Caenorhabditis remanei] (425 aa, Accession: gi 308473183 ref XP_003098817.1)	0.5	180	26	0.28	88	99
Hp_I15761_IG07705_L1121	BLASTX similarity to 78.44% ID to hypothetical protein CAEBREN_23086 [Caenorhabditis brenneri] (322 aa, Accession: gi 341889746 gb EGT45681.1)	0.18	41	144	1.47	368	16
Hp_I16083_IG08027_L1071	BLASTX similarity to 28.20% ID to Complement factor H [Ascaris suum] (1358 aa, Accession: gi 324499597 gb ADY39830.1)	0.41	72	85	0.19	42	186
Hp_I28418_IG20362_L498	BLASTX similarity to 45.24% ID to hypothetical protein CRE_02231 [Caenorhabditis remanei] (147 aa, Accession: gi 308510374 ref XP_003117370.1)	0.43	42	141	0.43	67	122
Hpb-APY-2	No BLASTX analysis performed; (File Apyrase 124-3 (iso 07051) 081110) 1062 nt	5.9	654	2	0.3	58	137
Hpb-GST-2	No BLASTX analysis performed; partial (no N-terminus) AF128959	1.07	96	60	0.79	138	59

a) Rank of 194 proteins in size fraction 11 or 262 candidates in charge fraction 25 determined by Mascot score, with a minimum score of 20

Supplementary Table 1 (related to Figure 1):

Candidate genes with emPAI peaking in size fractions 10-12 and charge fraction 23-27. Data shown for peak IL-33 suppressive fraction (size = 11, charge = 25).



Supplementary Figure 1 (Related to Figure 1):


A. Candidate protein selection strategy

B. Candidate protein EmpAI profile and IL-33 suppression profile in HES size (left panels) and charge (right panels) fractions. The 4 candidate proteins tested in Fig 2A are shown followed by a candidate not selected for further testing (Hp_I13075_IG05019_L1949), for comparison.

A


0	atgtatcgcctttttctcgcttttaggcttcctcaccttcacacgctgcaggtcagcgc	60
0	M Y R L F L A L G F L T F I N A A G O R	20
61	tgcagattcaccgatgtagaaagagacaaaggctacactggaatgctccttaaaggaagg	120
21	C R F T D V E R D K G Y T G M L L K G R	40
121	ttaagaaagacagctggaaacgggaggacggtagaattgatattgtggaagaggaaatcac	180
41	L R K T A G N G R T V E L I C G R G N H	60
181	aactacacctgcgagtcgggctgtttgaaggaaagtctccacggcaagcccgatgtgggt	240
61	N Y T C E S G V L K E S S P R O A R C G	80
241	tgcaagggaattctcgaatgctcttcgatatgcctaagggaagaacggccctcgccctg	300
81	C K G I L E M L F D M P K E E R P S P M	100
301	tacgactcagtcacctatgacccacgcccacaccccaacaactgtaggaaaggacggg	360
101	Y D S V T Y D P T P N T P T T V G K D G	120
361	atatggaacgggagtagattaccgcaatggctctacagtgaagccttattgcgatactgggt	420
121	I W N G V D Y R N G S T V K P Y C D T G	140
421	ccagtcacacgcatcctcctcctcctcctcctcctcctcctcctcctcctcctcctcct	480
141	P V I N G S S K A V C V S G K W V P T L	160
481	ggcgtctgcccacaaatgtgttcgatcggcagcttgaaggaaaatgggaaattcgtagac	540
161	G V C P K M C S I G S L K E N G K F V D	180
541	gtcacagcaacaactaaaggagacgagctcaaccccccgccaagggaacagacattgatt	600
181	V T A T T K G D E L N P P P R E Q T L I	200
601	cctatagtgcgtaaagttgacaaagacaagggtccaacacggcgtcaaagttgttgctctt	660
201	P I V R K V D K D K V O H G V K V V A L	220
661	tgtaaagccgaagattctacaactgccgctgaaggcgtccaggaattcgaatgtgacaac	720
221	C K A E D S T T A A E G V O E F E C D N	240
721	gggaagtgggaagccagagcccgtgccctgccctaa	756
241	G K W K P E P V P C P -	251

B




Supplementary Figure 2 (Related to Figure 2):

- HpARI cDNA sequence showing intron/exon boundaries (green/yellow highlight) and amino acid domains (coloured boxes/text, red = signal peptide, green = CCP1, salmon = CCP2, pink = CCP3)
- Coomassie-stained purified HpARI (2 µg), purified by nickel affinity chromatography.



Supplementary Figure 3 (Related to Figure 3):

- (A) Naive mouse lung cells were cultured in the presence of *Alternaria* (200 μ g/ml) and 10 μ g/ml HES or HpARI for 1 h or heat-treated (95°C for 30 min) HES or HpARI (HT HES or HT HpARI). IL-33 in supernatants was measured by ELISA.
- (B) Naive murine lung cells were subjected to freeze/thaw treatment (F/T) in the presence of HES, HpARI, HT HES or HT HpARI. IL-33 in supernatants was measured by ELISA.
- **** = $p < 0.0001$, ** = $p < 0.01$, N.S. = Not significant ($p > 0.05$), compared to *Alternaria* or freeze/thaw (F/T) control. Standard error of means of 3 replicates, representative of 2-3 repeat experiments.
- (C) IL-13-eGFP^{hi} proportion of ICOS+CD90.2+IL-33R+CD127+lineage⁻ ILC2s in the lung, 24 h after intranasal administration of *Alternaria* allergen and HpARI to IL-13-eGFP reporter mice. Results pooled from 2 repeat experiments. **** = $p < 0.0001$
- (D) Representative FACS plots of IL-13-eGFP^{hi} in live CD45+ lung lymphocytes from mouse shown in (C)
- (E) Representative FACS plots of IL-13-eGFP^{hi} cells (blue) and total CD45+ live lung lymphocytes (red) from an *Alternaria*-treated IL-13-eGFP reporter mouse.




Supplementary Figure 4 (Related to Figure 5):

(A) CMT-64 cell supernatants were taken after freeze-thaw and treated with HpARI or proteinase K-digested and heat-treated HpARI over a timecourse after thaw, as in Figure 5C

(B) Surface plasmon resonance was carried out using mIL-1 α or mIL-33 as a ligand for HpARI.

(C) HMGB1 western blots taken 15 min after Alternaria+/- HpARI administration. Pooled from 3 replicate experiments.



Supplementary Figure 5 (Related to Figure 7):

- (A)** CMT-64 cells were fixed and permeabilised, before staining with goat anti-mouse IL-33, followed by rabbit anti-goat IgG FITC secondary and counterstained with Hoechst 33342 nuclear stain. Scale bars indicate 100 μ m.
- (B)** CMT-64 cells were subjected to freeze/thaw necrosis in the presence of 5 μ g/ml HpARI and IL-33 in the supernatant measured by ELISA.
- (C)** CMT-64 cells were subjected to freeze/thaw necrosis in the presence of 5 μ g/ml HpARI_mCherry and IL-33 in the supernatant measured by ELISA. **** = $p < 0.0001$
- (D)** Immunoprecipitation of plasmid DNA by myc-tagged HpARI, but not by proteinase K and heat treated HpARI (pK) nor with isotype control antibody.
- (E)** Two views rotated by 180° along the y-axis depicting the electrostatic surface map of the 3-D model of HpARI CCP1 (calculated using APBS) revealing key residues contributing to the highly basic surface (coloured blue) that may confer DNA-binding properties; acidic surface residues are shown in red. A scaled range of -1kT to +1 kT was used, where k=Boltzman's constant and T= Temperature in Kelvins.